Renalytix Plc (LON:RENX – Get Free Report) shares were down 11.1% during trading on Friday . The company traded as low as GBX 1.60 and last traded at GBX 1.60. Approximately 428,751 shares were traded during mid-day trading, a decline of 53% from the average daily volume of 919,401 shares. The stock had previously closed at GBX 1.80.
Renalytix Stock Performance
The company has a debt-to-equity ratio of -118.57, a current ratio of 1.21 and a quick ratio of 2.42. The business has a 50-day simple moving average of GBX 1.94 and a 200 day simple moving average of GBX 4.26. The firm has a market cap of £6.99 million, a PE ratio of -0.40 and a beta of 1.97.
About Renalytix
Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).
Read More
- Five stocks we like better than Renalytix
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
- Snowflake and the Snowballing Impact of its AI Flywheel
- AI’s Biggest Bottleneck Could Make These 2 Stocks Soar
- These 3 Beaten-Down Stocks Just Saw $25 Million in Insider Buying
Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with MarketBeat.com's FREE daily email newsletter.
